Cart
sales@molnova.com
N′-(2-Chloroethyl)-N-(4-methylcyclohexyl)-N-nitrosourea
CAS No. 75219-93-1
N′-(2-Chloroethyl)-N-(4-methylcyclohexyl)-N-nitrosourea( —— )
Catalog No. M36553 CAS No. 75219-93-1
N′-(2-Chloroethyl)-N-(4-methylcyclohexyl)-N-nitrosourea has antitumor activity and is used in the treatment of Lewis lung and colon tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 172 | In Stock |
|
| 10MG | 254 | In Stock |
|
| 25MG | 392 | In Stock |
|
| 50MG | 551 | In Stock |
|
| 100MG | 762 | In Stock |
|
| 200MG | 1014 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameN′-(2-Chloroethyl)-N-(4-methylcyclohexyl)-N-nitrosourea
-
NoteResearch use only, not for human use.
-
Brief DescriptionN′-(2-Chloroethyl)-N-(4-methylcyclohexyl)-N-nitrosourea has antitumor activity and is used in the treatment of Lewis lung and colon tumors.
-
DescriptionN′-(2-Chloroethyl)-N-(4-methylcyclohexyl)-N-nitrosourea has antitumor activity and is used in the treatment of Lewis lung and colon tumors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number75219-93-1
-
Formula Weight247.72
-
Molecular FormulaC10H18ClN3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1CCC(N(N=O)C(NCCCl)=O)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
6-FAM-(Glu13·17·20)-...
6-FAM-(Glu13·17·20)-Osteocalcin (1-46) (mouse)
-
Cytidine 5'-diphosph...
Cytidine 5'-diphosphate trisodium salt can produce Cytidine triphosphate for synthesis of DNA and RNA through the transfer of phosphoryl group from ATP to cytidine monophosphate (CMP) catalyzed by uridine monophosphate kinase (UMPK).
-
Dermatan sulphate so...
Dermatan sulphate sodium, a glycosaminoglycan and thrombin inactivator, exhibits antithrombotic activity by selectively catalyzing the inactivation of thrombin via heparin cofactor II, without interaction with antithrombin III.
